Assuntos
Agamaglobulinemia/etiologia , Imunidade Celular , Imunodeficiência Combinada Severa/etiologia , Adenosina Desaminase/deficiência , Adenosina Desaminase/genética , Adenosina Desaminase/imunologia , Agamaglobulinemia/genética , Agamaglobulinemia/imunologia , Pré-Escolar , Consanguinidade , Feminino , Heterozigoto , História do Século XX , Humanos , Lactente , Imunodeficiência Combinada Severa/genética , Imunodeficiência Combinada Severa/imunologiaRESUMO
OBJECTIVES: The objectives of this study were to determine the presenting symptoms, healthcare utilization, and lost time from work and day care associated with acute rotavirus gastroenteritis. METHODS: During the winter to spring seasons of 2002-2003 or 2003-2004, children <36 months of age presenting with acute gastroenteritis to urban and suburban pediatric outpatient practices affiliated with 5 academic centers across the United States were enrolled in similarly designed studies. The case definition required >or=3 watery or looser-than-normal stools and/or forceful vomiting within a 24-hour period beginning Assuntos
Gastroenterite/epidemiologia
, Gastroenterite/virologia
, Infecções por Rotavirus/epidemiologia
, Doença Aguda
, Fatores Etários
, Assistência Ambulatorial
, Criança
, Pré-Escolar
, Estudos de Coortes
, Surtos de Doenças
, Feminino
, Gastroenterite/diagnóstico
, Gastroenterite/terapia
, Serviços de Saúde/estatística & dados numéricos
, Humanos
, Lactente
, Recém-Nascido
, Masculino
, Pediatria
, Estudos Prospectivos
, Infecções por Rotavirus/diagnóstico
, Infecções por Rotavirus/terapia
, Estados Unidos/epidemiologia
RESUMO
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.